alexa Bioequivalence of ticlopidine hydrochloride administered in single dose to healthy volunteers.
Biomedical Sciences

Biomedical Sciences

Journal of Bioanalysis & Biomedicine

Author(s): Marzo A, Dal Bo L, Rusca A, Zini P

Abstract Share this page

Abstract Ticlopidine hydrochloride (CAS 55142-85-3) is an inhibitor of platelet aggregation used in the management and prevention of thromboembolic disorders.A new formulation of ticlopidine hydrochloride (test) was compared to the reference Tiklid, present in the market, in order to assess their bioequivalence and to register the new formulation as a generic according to the Abbreviated New Drug Application (ANDA) procedure.Twenty-four healthy male volunteers were treated with the two formulations (one tablet containing 250mg of active ingredient) according to a single-dose, balanced, crossover, double-blind design with a washout between the two study periods. Plasma concentration of ticlopidine was assayed in timed samples over a 24h-period with a well-validated HPLC method with UV detection, which allowed 5ngml(-1) to be assayed as the lowest quantifiable concentration. The double-blind key was disclosed only after having completed the assay of unknown samples. From plasma concentrations, C(max), t(max), AUC(0-t), AUC(0- infinity ) and t(1/2) were evaluated through non-compartmental pharmacokinetic analysis. C(max) and AUCs were log(10)- transformed and statistically processed using crossover ANOVA. No statistically significant formulation, period, or sequence effect was encountered. Ninety percent confidence intervals of C(max) and AUCs were comprised in the stipulated 0.80-1.25 range. Similarly, Schuirmann's test led to statistically significant degrees on both the sides explored. Time to peak, t(max), processed with the non-parametric Kruskal-Wallis' test, did not show any statistically significant degree. According to guidelines operating in Europe, the test formulation of ticlopidine hydrochloride can be declared bioequivalent with the reference, both formulations in 250mg tablets.
This article was published in Pharmacol Res and referenced in Journal of Bioanalysis & Biomedicine

Relevant Expert PPTs

Relevant Speaker PPTs

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords